Dr. Michael A. Samara, M.D.
Heart Failure & Transplant Cardiology (Advanced Heart Failure and Transplant Cardiology Physician)
- Medicare participating
At a glance
- Medical school
- Clvlnd Clinic Lerner College of Med of Case Wstn Rsv University (2004)
- Years since graduation
- 22
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 609
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2004Medical school: Clvlnd Clinic Lerner College of Med of Case Wstn Rsv University
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Advanced Heart Failure and Transplant Cardiology Physician primary
MN license 55152 -
Cardiovascular Disease Physician
MN license 55152
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Map: Heart Failure & Transplant Cardiology per capita by county →
Where they work
Hospitals
- Abbott Northwestern Hospital Minneapolis, MN
- Mercy Hospital Coon Rapids, MN
- Allina Health Faribault Medical Center Faribault, MN
- New Ulm Medical Center New Ulm, MN
- Welia Health Mora, MN
Medical groups
- Allina Health System (3,842 clinicians)
- Minneapolis Heart Institute at Ridgeview Heart Center, LLC (54 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 609
- Services billed
- 1,217
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 203 | 201 |
| Established patient office or other outpatient visit, 30-39 minutes | 130 | 100 |
| Established patient office or other outpatient visit, 40-54 minutes | 110 | 86 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 101 | 52 |
| Critical care, first 30-74 minutes | 71 | 34 |
| Ultrasound of heart blood flow, valves and chambers, follow-up | 50 | 48 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 50 | 49 |
| Ultrasound of heart, follow-up | 47 | 45 |
| Evaluation of lower heart chamber assist device | 41 | 24 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 40 | 37 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Entresto (sacubitril/valsartan) Other prescribers in Minneapolis, MN | 306 |
| Spironolactone Other prescribers in Minneapolis, MN | 254 |
| Carvedilol Other prescribers in Minneapolis, MN | 219 |
| Farxiga (dapagliflozin propanediol) Other prescribers in Minneapolis, MN | 211 |
| Metoprolol Succinate Other prescribers in Minneapolis, MN | 201 |
| Eliquis (apixaban) Other prescribers in Minneapolis, MN | 191 |
| Jardiance (empagliflozin) Other prescribers in Minneapolis, MN | 189 |
| Vyndamax (tafamidis) | 179 |
| Atorvastatin Calcium Other prescribers in Minneapolis, MN | 146 |
| Torsemide Other prescribers in Minneapolis, MN | 133 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 1 companies. The companies reported $22,494 in research payments for these studies, mostly to the institutions running them.
- Assessment of CCM in HF With Higher Ejection Fraction
Impulse Dynamics (USA) Inc. · Recruiting · NCT05064709 - Post Approval Study (PAS) of the OPTIMIZER Smart and CCM Therapy
Impulse Dynamics (USA) Inc. · Active, not recruiting · NCT03970343
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.